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Abstract
Despite overall improvement in survival, morbidity, and quality of life of US patients with cancer, 
this progress is less prevalent in the population of adolescent and young adult patients with cancer, 
including those between the ages of 15 and 19 years. Evidence suggests that participation in 
clinical trials is associated with better survival outcomes among children and adolescents with 
cancer; however, adolescents have lower clinical trial participation rates compared with younger 
age cohorts. To better understand the unique concerns among adolescent patients with cancer, the 
Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention 
convened a workgroup of researchers and health care providers in the field of adolescent and 
young adult oncology and cancer survivorship to examine the barriers and challenges limiting the 
participation of adolescents in clinical trials and to define ways to improve upon these concerns. 
This article summarizes the activities of the workgroup and their suggestions for enhanced accrual.
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The number of cancer survivors in the United States has increased from 3 million to nearly 
12 million over the past 35 years, with marked improvements in cancer survival, morbidity, 
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and quality of life.1 These improvements, however, are less prevalent among adolescent 
patients with cancer who are between the ages of 15 and 19 years.2–6 Overall 5-year survival 
rates of adolescent patients diagnosed with cancer have remained stagnant since the 
mid-1980s.24 Despite evidence supporting the association between increased clinical trial 
participation and improved survival outcomes among patients with cancer,3,7–9 adolescents 
have lower clinical trial enrollment and participation rates (5%—34%) compared with 
younger children (>90%) 3,10–12
Referral patterns may contribute to lower enrollment rates among adolescents. Due to 
overlapping age criteria, cancer type, and geographic accessibility, adolescents suspected of 
having cancer can be referred to either pediatric or adult oncologists. However, the data 
suggest that older adolescents are more likely to be referred to adult oncologists,13 and 
indeed patients with cancer who are in this age group are more often treated at adult cancer 
centers than at pediatric cancer centers2,3,14–17 However, adolescents treated by adult 
oncologists are less likely to enroll in clinical trials compared with those treated by pediatric 
oncologists2–4,14,17,18 The overall low participation rates in clinical trials for adolescents 
may partially explain poor survival outcomes in this age group.19 For certain pediatric-type 
cancers, such as acute lymphoblastic leukemia, rhabdomyosarcoma, and Ewing’s sarcoma, 
evidence suggests that adolescents treated on pediatric protocols have better outcomes 
compared with those on adult protocols.20–24 In addition, treating adolescent patients who 
have cancer can be complicated due, in part, to the unique psychosocial considerations 
during this developmental stage. These challenges may include self-image, peer 
relationships, social and financial issues, and changes in autonomy versus dependency that 
can affect treatment decisions.25–27 Health care providers may lack awareness of these 
psychosocial issues and how they can negatively affect adherence to therapy, quality of life,
28
 and long-term outcomes.25,26,29,30
In response to the Carolyn Pryce Walker Conquer Childhood Cancer Act of 2008,31 which 
calls for “expansion and widespread implementation of activities that provide available 
information on treatment protocol to ensure early access to the best available therapies and 
clinical trials for pediatric cancers,” the Division of Cancer Prevention and Control at the 
Centers for Disease Control and Prevention (CDC) convened a workgroup of adolescent and 
young adult (AYA) cancer providers and researchers to examine the association between 
provider specialty (pediatric versus adult oncologist), clinical trial enrollment, and 
subsequent medical and psychosocial outcomes among adolescents between 15 and 19 years 
of age who have cancer. The main purpose of the workgroup was to identify practical issues 
and barriers that contribute to the limited participation of adolescent patients with cancer in 
clinical trials and to determine specific, actionable priorities to address these problems. The 
present article summarizes workgroup proceedings and highlights potential actions to 
improve clinical trial participation rates among adolescent patients with cancer and 
ultimately improve long-term outcomes.
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Between March and May 2012, the CDC convened a group of 20 US- and Canadian-based 
participants from a number of clinical and academic institutions, nonprofit organizations, 
and governmental agencies representing multiple fields, including pediatric and adult 
oncology, clinical research, behavioral science, health informatics, and clinical trials 
expertise. An invitation to participate in the workgroup was initially extended to 29 
individuals who were selected based on their history of first-authored, peer-reviewed 
manuscripts on related topics and area of expertise.A total of 18 experts, in addition to the 
workgroup chair and co-chair who were previously identified by CDC staff, accepted the 
invitation and participated in the workgroup meetings. CDC staff served as observers of the 
meeting and provided clarification on CDC-related activities for all participating workgroup 
members. After searches of the published literature on the topics, weekly discussions of the 
organizing committee, and development of review materials, three 2-hour Web-based 
meetings were convened on March 19, April 24, and May 23, 2012.
Webinar Sessions
To maximize interaction during the webinars, workgroup members were assigned specific 
topics related to clinical trial enrollment among adolescent patients with cancer. Each 
webinar session was divided into multiple discussion segments or subtopics. The topics were 
selected based on a literature review conducted on clinical trial enrollment and related 
outcomes among adolescents and further defined by the workgroup’s chair and co-chair with 
input from CDC staff. During the March and April webinars, discussions were preceded by 
presentations from selected workgroup members on current knowledge or projects relevant 
to a subtopic of the discussion. In addition, topics were assigned to members of the 
workgroup who were then responsible for crafting responses to specific questions in 
preparation for the webinar.
The March 2012 webinar focused on potential barriers to clinical trial enrollment among 
adolescents with cancer. The discussions centered around trends in clinical trial enrollment 
among 15-to 19-year-old patients with cancer, current and developing AYA oncology 
programs and their potential impact on clinical trial enrollment, and the unique psychosocial 
needs of adolescent patients. The April 2012 webinar explored the issue of where adolescent 
patients with cancer receive their diagnosis and treatment. Specifically, the discussion 
addressed the influence of geography on where adolescent patients with cancer seek care, 
differences between adult and pediatric centers in providing professional care, and the 
challenges impeding the enrollment into clinical trials of adolescent patients treated at adult 
cancer centers. The issue of adolescent patients with cancer and their psychosocial needs 
was revisited during the April webinar. The final webinar session in May 2012 focused on 
defining and discussing priority areas and future directions aimed toward improving clinical 
trial enrollment rates and subsequent outcomes of adolescents with cancer.
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Challenges and Suggested Priorities for Action
Discussions in all 3 sessions focused extensively on the various barriers and challenges that 
impede enrollment of adolescent patients with cancer into clinical trials. The workgroup 
members discussed a range of issues encompassing patient-, provider-, and institution-
related challenges that hinder adolescent patients from receiving comprehensive cancer care 
associated with clinical trial participation. The workgroup participants also provided input 
on how to address the identified challenges and suggested actions that could be pursued by 
oncologists, nurses,mental health providers, patients, organizations, and agencies to improve 
clinical trial enrollment rates and care for adolescent patients with cancer.
The workgroup identified 5 issues as the most important barriers: (1) low referral rates of 
adolescent patients with cancer to pediatric cancer centers; (2) limited availability of clinical 
trials for certain cancers; (3) physician-related barriers limiting clinical trial accrual; (4) 
institutional barriers impeding collaboration between pediatric and adult oncologists on 
clinical trials; and (5) unique psychosocial needs of adolescent patients with cancer.
Low Referral Rates—The first barrier identified by the workgroup was low referral rates 
of adolescent patients with cancer to pediatric cancer centers and other centers with qualified 
clinical trials for these patients.
Workgroup participants reported that policymakers, cancer center directors, community 
health professional leaders, and AYA specialists may use the National Comprehensive 
Cancer Network guidelines on AYA oncology that were published in February 2012.32 
These guidelines begin by recommending consideration of referral to an appropriate 
National Cancer Institute (NCI)-sponsored medical institution. Specialists in the AYA 
oncology field may benefit by developing effective outreach messages targeting primary care 
providers (PCPs) and patients in their communities to promote services and treatment 
options available to adolescent patients with cancer through their programs and cancer 
centers. These messages may consider important factors that influence the PCP’s referral 
decisions and highlight the unique medical and psychosocial needs of adolescent patients 
who require additional support; this support may be available through pediatric cancer 
centers. Outreach efforts can also increase general awareness about clinical cancer trials and 
the availability of trials in the communities where these oncologists practice. It may be of 
benefit for oncologists, organizations, and agencies working on AYA-related issues to 
expand clinical trial educational efforts beyond practicing PCPs. The “Stop A Doc” 
campaign, which encourages greater engagement of AYA cancer patients with their health 
care providers, may provide a good model for these efforts.33 AYA organizations can use 
popular Web sites and other social media tools managed by prominent cancer organizations 
and professional provider organizations to target adolescent patients and PCPs and to 
increase awareness about the care options available for adolescent patients with cancer. The 
AYA organizations can also use Web site advertising tools to direct traffic to appropriate 
AYA cancer Web sites.
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Clinical Trial Availability—The second barrier identified by the workgroup was the 
limited availability of clinical trials for certain cancers that are common among adolescent 
patients. In an effort to increase demand for more clinical trials available to adolescent 
patients with cancer, workgroup members recommended that AYA organizations and 
agencies engage adolescent patients and patient rights groups in informing health care 
providers to consider and participate in clinical trials for adolescent patients with cancer. As 
more evidence becomes available on the pharmacodynamics, pharmacokinetics, and effects 
of therapy on young patients, the 18-year lower age limit for adult clinical trials may need to 
be reevaluated. For cancers with highly favorable treatment outcomes in the adolescent 
population (eg, Hodgkin’s lymphoma, germ cell tumors), new clinical trials can be designed 
with a focus on reducing therapy-related toxicities. Treatment protocols of clinical trials 
appropriate for adolescent patients should include goals specific to this population. 
Collaboration between pediatric and adult oncologists may be leveraged to design AYA-
focused clinical trials for cancers common among this group. The reorganization of the NCI-
sponsored clinical trial enterprise34 may consider including a focus on AYA clinical trials 
and specifically those with potential application to adolescents. The annual renewal of NCI-
designated cancer centers that are recipients of Cancer Center Support Grants may also 
require the reporting of the age of patients accrued to clinical trials, with a specific metric 
for the 15- to 19-year- old and 20- to 39-year-old age groups.
Physician-Related Barriers—The third barrier identified by the workgroup was 
physician-related barriers limiting clinical trial accrual among adolescent patients with 
cancer. This barrier may include issues such as the lack of standards of care for the common 
cancers in adolescents and limited participation of adult oncologists in pertinent adolescent 
cancer clinical trials. Workgroup participants recommended increasing collaboration 
between pediatric and adult oncologists to increase clinical trial enrollment for adolescent 
patients with cancer. Barriers currently limiting physician participation and collaboration on 
clinical trials relevant to adolescent patients, such as the lack of financial incentives and low 
accrual rates, need to be taken into consideration when planning these efforts. Differences in 
pediatric and adult oncologists’ views on the purposes of clinical trials may also need to be 
reconciled to increase clinical trial enrollment. Similar to increasing awareness among PCPs 
and in local communities, the specific needs of adolescent patients must be realized in the 
oncology arena. Reaching treatment consensus among pediatric and adult oncologists must 
be prioritized for AYA common cancers to establish standard of care. In addition, increased 
collaboration between pediatric and adult oncologists may be more effective if undertaken at 
the time when AYA-relevant clinical trials are designed. Elements of successful collaborative 
clinical trial efforts between pediatric and adult cooperative groups should be thoroughly 
examined to understand existing barriers and challenges so that future partnerships and 
models of care can be developed.
Institutional Barriers—The fourth barrier identified by the workgroup was institutional 
barriers impeding collaboration of pediatric and adult oncologists in clinical trials and 
limiting accrual of adolescents in clinical trials. An example of this barrier was the lack of 
recognition of centralized institutional review boards (IRBs) by individual cancer 
institutions. Academic institutions involved in collaborative multisite research often obtain 
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approval from their own individual IRBs. However, many institutions are unwilling to defer 
IRB approval to centralized IRBs for various reasons.35 This action results in the use of 
excessive resources on IRB applications, reviews, and duplication of efforts at multiple 
institutions. Workgroup members discussed potential solutions, which may include 
modification of clinical trial IRB issues (eg, single IRB of record, recognition of centralized 
IRBs by cancer institutions), reimbursement of adult specialists participating in pediatric 
clinical trials, and examination of geographic barriers to trial implementation (eg, location of 
treatment versus location of principal trial investigator).
Unique Psychosocial Needs of Adolescent Patients With Cancer—The fifth 
barrier identified by the workgroup was the unique psychosocial needs of adolescent patients 
with cancer. Although it is well recognized that adolescents have unique psychosocial needs, 
it is not clear how these issues have an impact on clinical trial participation. Overall, more 
recent research on AYA psycho-oncology tends to have focused on the “young adults” of 
this spectrum, and there is much to learn about adolescent patients with cancer, especially in 
terms of their input regarding treatment choices and adherence to treatment. Integration of 
psychosocial goals into the treatment protocols of clinical trials relevant to adolescent 
patients is needed and could help explain how participation of adolescents in clinical trials 
affects the psychosocial outcomes of participants compared with nonparticipants. An 
example of this process is the distress screening mandate that all Commission on Cancer-
approved hospitals must adhere to.36 Clinicians may benefit from receiving training on how 
to have developmentally relevant discussions with their adolescent patients about issues 
related to their care, including presenting information on clinical trials. AYA groups and 
organizations may work with cancer organizations to identify and engage public figures who 
were diagnosed with cancer during adolescence to share their experience with adolescent 
cancer patients.
The workgroup also recommended additional efforts to support the development of AYA 
cancer peer groups to offer psychosocial support to adolescent patients with cancer through 
existing networks of cancer survivors or by forming new groups at NCI-designated cancer 
centers. AYA organizations may consider developing training materials for peer support 
specific to AYA that can be disseminated to cancer peer support groups.
The role of parents in decision-making for adolescents with cancer was also discussed. An 
adolescent’s transition from dependent to autonomous decision making may depend on his 
or her level of cognitive and emotional maturity. Although panelists noted that an adolescent 
may have the desire and/or developmental maturity to assume more responsibility in 
decision-making, there are ethical and legal complications regarding consent and assent that 
may arise when parents and adolescents do not agree about clinical trial enrollment. 
Although it was noted that parents have the legal right to make clinical trial enrollment 
decisions, with or without the adolescent’s assent, increased communication and 
collaboration between clinicians, adolescent patients, and parents are needed to ensure 
cooperation and adherence to treatment and clinical trial enrollment, as well as to alleviate 
emotional concerns associated with relinquishing or assuming decision-making 
responsibilities.
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Adolescent patients with cancer have unique experiences as they face the dual stress of 
having a life-threatening disease while dealing with the challenges of transitioning from 
childhood to adulthood.37 Despite significant progress in cancer care and survivorship, 
adolescent patients have seen less improvement compared with other age groups. Poor 
outcomes among adolescent patients with cancer may ultimately be attributed to the limited 
awareness about their distinctive treatment and care needs among the medical community in 
addition to the lack of an organized body of research and a well-formulated discipline in 
medicine devoted to this specific group of patients.3,7,28 Even within the expanding AYA 
oncology field, the focus on young adults may overshadow the issues that uniquely affect the 
adolescent cancer population.34 The limited knowledge about issues relevant to the care of 
adolescent patients with cancer emphasizes the need for more initiatives focusing on this 
population. Convening this workgroup offered an opportunity for researchers and providers 
working in the AYA oncology field to discuss this frequently overlooked group. The 
suggestions put forth by workgroup members highlight the importance of engaging various 
stakeholders of the AYA community to address the problems and barriers hindering the 
participation and enrollment of adolescents with cancer into clinical trials and hence limiting 
the care options for these patients.
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